634 related articles for article (PubMed ID: 15639300)
1. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
3. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
4. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
6. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression.
Sanz MJ; Cortijo J; Morcillo EJ
Pharmacol Ther; 2005 Jun; 106(3):269-97. PubMed ID: 15922015
[TBL] [Abstract][Full Text] [Related]
7. PDE4 inhibitors in COPD--a more selective approach to treatment.
Vignola AM
Respir Med; 2004 Jun; 98(6):495-503. PubMed ID: 15191033
[TBL] [Abstract][Full Text] [Related]
8. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast for asthma and chronic obstructive pulmonary disease.
Cowan C
Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
11. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Giembycz MA
Expert Opin Investig Drugs; 2001 Jul; 10(7):1361-79. PubMed ID: 11772257
[TBL] [Abstract][Full Text] [Related]
12. Cilomilast.
Schachter EN
Drugs Today (Barc); 2006 Apr; 42(4):237-47. PubMed ID: 16703120
[TBL] [Abstract][Full Text] [Related]
13. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 4 inhibitors for the treatment of COPD.
Sturton G; Fitzgerald M
Chest; 2002 May; 121(5 Suppl):192S-196S. PubMed ID: 12010850
[TBL] [Abstract][Full Text] [Related]
16. [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases].
Xia XD; Dai YR; Xu ZJ
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jan; 27(1):57-9. PubMed ID: 14989829
[No Abstract] [Full Text] [Related]
17. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
Tatlicioğlu T
Tuberk Toraks; 2008; 56(4):472-84. PubMed ID: 19123088
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
19. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
Kreutzkamp B
Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
[TBL] [Abstract][Full Text] [Related]
20. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
